HRP20100580T1 - 4-anilinokvinolin-3-karboksamidi kao inhibitori csf-1r kinaze - Google Patents
4-anilinokvinolin-3-karboksamidi kao inhibitori csf-1r kinaze Download PDFInfo
- Publication number
- HRP20100580T1 HRP20100580T1 HR20100580T HRP20100580T HRP20100580T1 HR P20100580 T1 HRP20100580 T1 HR P20100580T1 HR 20100580 T HR20100580 T HR 20100580T HR P20100580 T HRP20100580 T HR P20100580T HR P20100580 T1 HRP20100580 T1 HR P20100580T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- compound
- formula
- image
- pharmaceutically acceptable
- Prior art date
Links
- MOXCMUMGZFALMQ-UHFFFAOYSA-N 4-anilinoquinoline-3-carboxamide Chemical class NC(=O)C1=CN=C2C=CC=CC2=C1NC1=CC=CC=C1 MOXCMUMGZFALMQ-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 27
- 150000003839 salts Chemical class 0.000 claims abstract 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 11
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 48
- -1 nitro, formyl Chemical group 0.000 claims 21
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 238000006243 chemical reaction Methods 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000004452 carbocyclyl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical group 0.000 claims 3
- IBHNEKVLDKCEQY-UHFFFAOYSA-N 4-(2,4-difluoroanilino)-7-ethoxy-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide Chemical compound C=12C=C(N3CCN(C)CC3)C(OCC)=CC2=NC=C(C(N)=O)C=1NC1=CC=C(F)C=C1F IBHNEKVLDKCEQY-UHFFFAOYSA-N 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- KOGCUICFFHZSOM-UHFFFAOYSA-N 4-(2,3-dichloroanilino)-7-ethoxy-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide Chemical compound C=12C=C(N3CCN(C)CC3)C(OCC)=CC2=NC=C(C(N)=O)C=1NC1=CC=CC(Cl)=C1Cl KOGCUICFFHZSOM-UHFFFAOYSA-N 0.000 claims 1
- KGVQZJHSSDOJHG-UHFFFAOYSA-N 4-(2,4-difluoroanilino)-7-(2-methoxyethoxy)-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide Chemical compound C=12C=C(N3CCN(C)CC3)C(OCCOC)=CC2=NC=C(C(N)=O)C=1NC1=CC=C(F)C=C1F KGVQZJHSSDOJHG-UHFFFAOYSA-N 0.000 claims 1
- HJBIOYGBCCKLGS-UHFFFAOYSA-N 4-(2-fluoro-4-methylanilino)-7-(2-methoxyethoxy)-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide Chemical compound C=12C=C(N3CCN(C)CC3)C(OCCOC)=CC2=NC=C(C(N)=O)C=1NC1=CC=C(C)C=C1F HJBIOYGBCCKLGS-UHFFFAOYSA-N 0.000 claims 1
- AQUQOGBEYFTABQ-UHFFFAOYSA-N 4-(2-fluoro-4-methylanilino)-7-(2-methoxyethoxy)-6-(4-propan-2-ylpiperazin-1-yl)quinoline-3-carboxamide Chemical compound C=12C=C(N3CCN(CC3)C(C)C)C(OCCOC)=CC2=NC=C(C(N)=O)C=1NC1=CC=C(C)C=C1F AQUQOGBEYFTABQ-UHFFFAOYSA-N 0.000 claims 1
- BGYIPLCGZDFBKR-UHFFFAOYSA-N 4-(2-fluoro-5-methylanilino)-7-(2-methoxyethoxy)-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide Chemical compound C=12C=C(N3CCN(C)CC3)C(OCCOC)=CC2=NC=C(C(N)=O)C=1NC1=CC(C)=CC=C1F BGYIPLCGZDFBKR-UHFFFAOYSA-N 0.000 claims 1
- VLGRXJVJJVSIPO-UHFFFAOYSA-N 4-(3-chloro-2-fluoroanilino)-7-ethoxy-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide Chemical compound C=12C=C(N3CCN(C)CC3)C(OCC)=CC2=NC=C(C(N)=O)C=1NC1=CC=CC(Cl)=C1F VLGRXJVJJVSIPO-UHFFFAOYSA-N 0.000 claims 1
- BBUGAAUSTUTTDJ-UHFFFAOYSA-N 7-ethoxy-4-(2-fluoro-4-methylanilino)-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide Chemical compound C=12C=C(N3CCN(C)CC3)C(OCC)=CC2=NC=C(C(N)=O)C=1NC1=CC=C(C)C=C1F BBUGAAUSTUTTDJ-UHFFFAOYSA-N 0.000 claims 1
- HTAUJXQLLAAXGC-UHFFFAOYSA-N 7-ethoxy-4-(2-fluoro-5-methylanilino)-6-(4-methylpiperazin-1-yl)quinoline-3-carboxamide Chemical compound C=12C=C(N3CCN(C)CC3)C(OCC)=CC2=NC=C(C(N)=O)C=1NC1=CC(C)=CC=C1F HTAUJXQLLAAXGC-UHFFFAOYSA-N 0.000 claims 1
- ZRFGJUOYZNQOJB-UHFFFAOYSA-N 7-ethoxy-4-(2-fluoro-5-methylanilino)-6-(4-propan-2-ylpiperazin-1-yl)quinoline-3-carboxamide Chemical compound C=12C=C(N3CCN(CC3)C(C)C)C(OCC)=CC2=NC=C(C(N)=O)C=1NC1=CC(C)=CC=C1F ZRFGJUOYZNQOJB-UHFFFAOYSA-N 0.000 claims 1
- 229910003813 NRa Inorganic materials 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74485706P | 2006-04-14 | 2006-04-14 | |
| US86509006P | 2006-11-09 | 2006-11-09 | |
| PCT/GB2007/001338 WO2007119046A1 (en) | 2006-04-14 | 2007-04-12 | 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100580T1 true HRP20100580T1 (hr) | 2010-11-30 |
Family
ID=38268859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100580T HRP20100580T1 (hr) | 2006-04-14 | 2010-10-25 | 4-anilinokvinolin-3-karboksamidi kao inhibitori csf-1r kinaze |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20090054411A1 (da) |
| EP (1) | EP2010496B1 (da) |
| JP (1) | JP2009533405A (da) |
| KR (1) | KR20080112380A (da) |
| CN (1) | CN101466682A (da) |
| AR (1) | AR060508A1 (da) |
| AT (1) | ATE478849T1 (da) |
| AU (1) | AU2007238372A1 (da) |
| BR (1) | BRPI0710191A2 (da) |
| CA (1) | CA2649146A1 (da) |
| CY (1) | CY1111203T1 (da) |
| DE (1) | DE602007008710D1 (da) |
| DK (1) | DK2010496T3 (da) |
| EC (1) | ECSP088828A (da) |
| HK (1) | HK1126199A1 (da) |
| HR (1) | HRP20100580T1 (da) |
| IL (1) | IL194424A0 (da) |
| MX (1) | MX2008013212A (da) |
| NO (1) | NO20084202L (da) |
| PL (1) | PL2010496T3 (da) |
| PT (1) | PT2010496E (da) |
| RS (1) | RS51483B (da) |
| RU (1) | RU2008144806A (da) |
| SI (1) | SI2010496T1 (da) |
| TW (1) | TW200808732A (da) |
| UY (1) | UY30282A1 (da) |
| WO (1) | WO2007119046A1 (da) |
| ZA (1) | ZA200808599B (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200829555A (en) * | 2006-11-10 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
| CL2008000191A1 (es) | 2007-01-25 | 2008-08-22 | Astrazeneca Ab | Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer. |
| EP2310375A1 (en) * | 2008-05-07 | 2011-04-20 | AstraZeneca AB | Chemical compounds |
| TW201041869A (en) | 2009-05-14 | 2010-12-01 | Japan Tobacco Inc | Azetidine compound and pharmaceutical use thereof |
| AU2011282588B2 (en) | 2010-07-30 | 2016-01-07 | Oncotherapy Science, Inc. | Quinoline derivatives and MELK inhibitors containing the same |
| JP2014504269A (ja) * | 2010-11-05 | 2014-02-20 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド | 化学化合物 |
| HUE032754T2 (en) * | 2011-05-05 | 2017-10-30 | Novartis Ag | CSF-1R inhibitors for the treatment of brain tumors |
| WO2012151541A1 (en) * | 2011-05-05 | 2012-11-08 | Novartis Ag | Csf-1r inhibitors for treatment of brain tumors |
| CN102584852B (zh) * | 2011-12-30 | 2014-08-13 | 厦门大学 | 真菌代谢产物桥南霉素及其制备方法和应用 |
| TWI623536B (zh) * | 2012-01-19 | 2018-05-11 | 腫瘤療法 科學股份有限公司 | １,５－萘啶衍生物與含此之ｍｅｌｋ抑制劑 |
| GB201211310D0 (en) * | 2012-06-26 | 2012-08-08 | Chroma Therapeutics Ltd | CSF-1R kinase inhibitors |
| CA2900652C (en) | 2013-02-15 | 2021-05-04 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| JP2016510000A (ja) | 2013-02-20 | 2016-04-04 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物およびその使用 |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| AU2014342042B2 (en) | 2013-11-01 | 2017-08-17 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US10722517B2 (en) | 2015-05-08 | 2020-07-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for treatment of glioma |
| EP3509422A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| WO2018048750A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509421A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| CN109700794B (zh) * | 2017-03-01 | 2021-01-08 | 浙江大学 | 腙结构类型雄激素受体拮抗剂及其应用 |
| AU2021348477B2 (en) * | 2020-09-23 | 2023-12-21 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Csf1r kinase inhibitor and use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| CA2344169C (en) * | 1998-09-29 | 2011-07-19 | American Cyanamid Company | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
| SI2253620T1 (sl) * | 1998-09-29 | 2014-06-30 | Wyeth Holdings Llc | Substituirani 3-cianokinolini kot inhibitorji protein tirozin-kinaz |
| SE0101675D0 (sv) * | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
| US7598258B2 (en) * | 2002-05-01 | 2009-10-06 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor |
| US7618975B2 (en) * | 2003-07-03 | 2009-11-17 | Myriad Pharmaceuticals, Inc. | 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| CA2537978C (en) * | 2003-09-15 | 2011-08-02 | Wyeth | Substituted quinolines as protein tyrosine kinase enzyme inhibitors |
| SE0400284D0 (sv) * | 2004-02-10 | 2004-02-10 | Astrazeneca Ab | Novel compounds |
| WO2006124996A2 (en) * | 2005-05-17 | 2006-11-23 | Supergen, Inc. | Inhibitors of polo-like kinase-1 |
-
2007
- 2007-04-12 RS RSP-2010/0476A patent/RS51483B/en unknown
- 2007-04-12 CN CNA2007800214225A patent/CN101466682A/zh active Pending
- 2007-04-12 JP JP2009504814A patent/JP2009533405A/ja active Pending
- 2007-04-12 AT AT07732381T patent/ATE478849T1/de active
- 2007-04-12 AR ARP070101556A patent/AR060508A1/es not_active Application Discontinuation
- 2007-04-12 CA CA002649146A patent/CA2649146A1/en not_active Abandoned
- 2007-04-12 SI SI200730379T patent/SI2010496T1/sl unknown
- 2007-04-12 PT PT07732381T patent/PT2010496E/pt unknown
- 2007-04-12 KR KR1020087027925A patent/KR20080112380A/ko not_active Application Discontinuation
- 2007-04-12 TW TW096112797A patent/TW200808732A/zh unknown
- 2007-04-12 DE DE602007008710T patent/DE602007008710D1/de active Active
- 2007-04-12 EP EP07732381A patent/EP2010496B1/en active Active
- 2007-04-12 MX MX2008013212A patent/MX2008013212A/es active IP Right Grant
- 2007-04-12 UY UY30282A patent/UY30282A1/es unknown
- 2007-04-12 WO PCT/GB2007/001338 patent/WO2007119046A1/en active Application Filing
- 2007-04-12 BR BRPI0710191-0A patent/BRPI0710191A2/pt not_active IP Right Cessation
- 2007-04-12 PL PL07732381T patent/PL2010496T3/pl unknown
- 2007-04-12 RU RU2008144806/04A patent/RU2008144806A/ru not_active Application Discontinuation
- 2007-04-12 DK DK07732381.4T patent/DK2010496T3/da active
- 2007-04-12 AU AU2007238372A patent/AU2007238372A1/en not_active Abandoned
-
2008
- 2008-09-28 IL IL194424A patent/IL194424A0/en unknown
- 2008-10-08 NO NO20084202A patent/NO20084202L/no not_active Application Discontinuation
- 2008-10-08 ZA ZA200808599A patent/ZA200808599B/xx unknown
- 2008-10-13 US US12/250,314 patent/US20090054411A1/en not_active Abandoned
- 2008-10-17 EC EC2008008828A patent/ECSP088828A/es unknown
-
2009
- 2009-05-19 HK HK09104565.8A patent/HK1126199A1/xx not_active IP Right Cessation
-
2010
- 2010-10-21 CY CY20101100943T patent/CY1111203T1/el unknown
- 2010-10-25 HR HR20100580T patent/HRP20100580T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1126199A1 (en) | 2009-08-28 |
| PL2010496T3 (pl) | 2011-01-31 |
| NO20084202L (no) | 2008-10-08 |
| JP2009533405A (ja) | 2009-09-17 |
| CA2649146A1 (en) | 2007-10-25 |
| PT2010496E (pt) | 2010-10-13 |
| KR20080112380A (ko) | 2008-12-24 |
| CY1111203T1 (el) | 2015-06-11 |
| AR060508A1 (es) | 2008-06-25 |
| SI2010496T1 (sl) | 2010-11-30 |
| DE602007008710D1 (en) | 2010-10-07 |
| ZA200808599B (en) | 2009-11-25 |
| EP2010496A1 (en) | 2009-01-07 |
| EP2010496B1 (en) | 2010-08-25 |
| ECSP088828A (es) | 2008-11-27 |
| UY30282A1 (es) | 2007-11-30 |
| ATE478849T1 (de) | 2010-09-15 |
| CN101466682A (zh) | 2009-06-24 |
| TW200808732A (en) | 2008-02-16 |
| RU2008144806A (ru) | 2010-05-20 |
| IL194424A0 (en) | 2009-08-03 |
| BRPI0710191A2 (pt) | 2012-06-05 |
| US20090054411A1 (en) | 2009-02-26 |
| RS51483B (en) | 2011-04-30 |
| WO2007119046A1 (en) | 2007-10-25 |
| AU2007238372A1 (en) | 2007-10-25 |
| DK2010496T3 (da) | 2010-11-08 |
| MX2008013212A (es) | 2008-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100580T1 (hr) | 4-anilinokvinolin-3-karboksamidi kao inhibitori csf-1r kinaze | |
| CN100384852C (zh) | 作为糖原磷酸化酶抑制剂的杂环酰胺衍生物 | |
| HRP20160852T1 (hr) | Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze | |
| HRP20171748T1 (hr) | 6-amino kinazolina ili 3-cijano derivati kinolina, postupci priprave i njihova farmaceutska uporaba | |
| CA2403514A1 (en) | 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors | |
| RS50932B (sr) | N-oksidi kao prolekovi 4-fenil-piridinskih derivata koji su antagonisti nk1 receptora | |
| HRP20160002T1 (hr) | Bicikliäśki heterocikliäśki spojevi kao inhibitori protein tirozin kinaze | |
| BG104112A (en) | 1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine derivatives and pharmaceutical compositions containing them | |
| HRP20110156T1 (hr) | Monociklički heterocikli kao inhibitori kinaze | |
| HRP20090533T1 (en) | Indolyl derivatives as liver-x-receptor modulators | |
| CA2989722C (en) | Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy | |
| NO20024154D0 (no) | Pyrimidinforbindelser | |
| MX2009011212A (es) | Derivados de triazolopiridina carboxamida y triazolopirimidina carboxamida, su preparacion y su aplicacion terapeutica. | |
| HUP0103987A2 (en) | Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates | |
| MX2009011213A (es) | Derivados de triazolopiridina carboxamida y triazolopirimidina carboxamida, su preparacion y su aplicacion terapeutica. | |
| RS51574B (sr) | JEDINJENJA PIROLO (2,3-d) PIRIMIDINA | |
| YU9194A (sh) | Derivati pipolo-piridina | |
| CA2668997A1 (en) | 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors | |
| JP2006522812A5 (da) | ||
| ATE218141T1 (de) | Erythromycin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| JP2012511588A5 (da) | ||
| RU2006112845A (ru) | Производные хиназолина | |
| HRP20070117T3 (en) | Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type ii diabetes | |
| WO2008006969A3 (fr) | Nouveaux derives tetracycuques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| DE60008917D1 (de) | Neue 1,8-naphtyridin-2(1h)-on-derivate |